Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery (NCT05936580)

🧪 Interventions in This Study

• Nuwiq (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (16 Sites)

• UT Health San Antonio — San Antonio, Texas
• Helsinki University Hospital,Coagulation Disorder Unit — Helsinki,
• Avenue de la République — Chambray-lès-Tours,
• CHU de Nantes Hôtel-Dieu — Nantes,
• Chu de Strasbourg — Stasbourg,
• Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin — Bonn,
• Gerinnungszentrum Rhein-Ruhr — Duisburg,
• Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik — Hamburg,
• Aziendo Ospedaliera "Puglieze Ciaccio" — Catanzaro,
• Policlinico "P. Giaconne" — Palermo,
• Clinical Center for Serbia — Belgrade,
• Hospital Universitario la Paz — Madrid,
• Hospital Universitario Virgen del Rocio — Seville,
• Insel Spital Bern — Bern,
• St. James's University Hospital — Leeds,
• Centro Hospitalario Pereira Rossell — Montevideo,

📞 Contact the Study Coordinator

Phone: +41795859042

Email: cristina.solomon@octapharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hemophilia A

• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" — Little Rock, Arkansas
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Los Angeles, California
• Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A — Milwaukee, Wisconsin
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Gainesville, Florida
• A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A — Gilbert, Arizona
• Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults — Mountain View, California

Explore by condition: All Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.